VERUVeru
About Veru
Veru (NASDAQ:VERU) focuses on developing novel medicines for the management of breast cancer and severe COVID-19. With a dedicated team working steadfastly, their projects range from early-stage research to late-stage clinical trials aimed at addressing unmet medical needs. Furthermore, Veru is traded on the NASDAQ under the symbol VERU. The company's objective is not only to advance the treatment options available for breast cancer and serious COVID-19 cases but also to enhance patient outcomes through innovative therapeutic solutions. Their commitment to research and development in these critical areas underscores their dedication to improving health and making a meaningful impact in the lives of patients worldwide.
What is VERU known for?
Snapshot
Public US
Ownership
1971
Year founded
189
Employees
Miami, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Miami, US
Produtos e/ou serviços de Veru
- Development of VERU-111, an oral selective antitubulin agent targeting metastatic breast cancer and COVID-19 associated ARDS.
- Commercialization of FC2 Female Condom, designed for dual protection against unwanted pregnancies and sexually transmitted infections.
- Progression of Enobosarm, a novel oral androgen receptor targeting agent, for androgen receptor positive metastatic breast cancer.
- Advancement of VERU-100, a peptide formulation for androgen deprivation therapy in advanced prostate cancer treatment.
- Exploration of zuclomiphene citrate, aimed at treating hot flashes in men undergoing hormone therapy for prostate cancer.
- Marketing of TADFIN, a combination therapy for benign prostatic hyperplasia and erectile dysfunction.
equipe executiva do Veru
- Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President & CEO
- Dr. Harry D. Fisch F.A.C.S., M.D.Vice Chairman & Chief Corporate Officer
- Dr. K. Gary Barnette Ph.D.Chief Scientific Officer
- Ms. Michele Greco C.P.A.CFO & Chief Administrative Officer
- Mr. Samuel FischExecutive Director of Investor Relations & Corporate Communications
- Mr. Philip R. Greenberg J.D.Executive VP & General Counsel
- Mr. Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate Development
- Mr. Martin TaylerExecutive Vice President of FC2 Global Operations
- Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical Operations
- Dr. Gary Bird Ph.D.Executive Vice President of Quality & Regulatory Affairs